Dallas, TX – March 19, 2026 – Verily, the precision health company spun out of Alphabet, has secured $300 million in new funding, marking a significant step towards its independence and a sharpened focus on artificial intelligence-driven healthcare solutions. The investment, led by Series X Capital with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, will fuel the company’s AI-native precision health platform strategy.
This funding round represents a pivotal moment for Verily, transitioning the company from an LLC to a corporation, now officially named Verily Health Inc. The move signals a strategic shift, allowing Verily to operate with greater autonomy and forge broader partnerships across the healthcare and technology landscapes. Alphabet, even as remaining a significant minority investor, will no longer hold a controlling stake in the company it initially incubated a decade ago, a change designed to foster greater vendor neutrality within the enterprise healthcare sector. This independence is crucial, as many healthcare organizations are hesitant to deeply integrate with companies perceived as extensions of large technology corporations.
Verily’s AI-Driven Precision Health Vision
The $300 million investment will be directed towards accelerating Verily’s development of an AI-native precision health platform. This platform aims to harmonize fragmented healthcare data, enabling the deployment of actionable intelligence into both research and clinical workflows. According to Stephen Gillett, Chairman and CEO of Verily, the funding will assist deliver “the next generation of healthcare – one that is as precise as it is personal.” Verily’s announcement highlights the company’s commitment to integrating clinical rigor with the power of AI.
The necessitate for such a platform stems from the challenges inherent in modern healthcare data management. Hospitals and research institutions often struggle with siloed data systems, making it difficult to gain a comprehensive view of patient health and hindering the development of effective treatments. Verily’s platform seeks to address this issue by providing a unified environment for data analysis and insight generation.
Strategic Partnerships Drive Expansion
Verily has already begun establishing key partnerships to expand the reach and impact of its platform. A recent collaboration with Samsung involves utilizing the Galaxy Watch to accelerate clinical research through biomarker development on the Pre platform. This partnership leverages wearable technology to collect real-time health data, offering new opportunities for early disease detection and personalized treatment plans. HIT Consultant reports that this collaboration demonstrates Verily’s commitment to integrating its platform with existing consumer technologies.
Another strategic partnership with Salesforce focuses on integrating the Verily Pre Platform with Agentforce Health. This integration aims to power enterprise precision health solutions, providing healthcare organizations with the tools they need to deliver more targeted and effective care. The Pre Platform, a core component of Verily’s strategy, is designed to facilitate the development and deployment of AI-powered healthcare applications.
UCHealth and University of Colorado Anschutz Join the Investment
The participation of UCHealth and the University of Colorado Anschutz in the funding round underscores the growing interest in precision health solutions among leading healthcare providers and academic institutions. UCHealth, a prominent healthcare system in Colorado, and the University of Colorado Anschutz Medical Campus are actively utilizing the Verily Pre platform to transform clinical research and care delivery. Becker’s Hospital Review notes that this involvement signifies a commitment to innovation and a desire to leverage AI to improve patient outcomes.
The University of Colorado Anschutz Medical Campus is a leading academic medical center known for its research and clinical excellence. Its partnership with Verily will likely accelerate the development of new precision health technologies and contribute to advancements in medical knowledge. UCHealth’s involvement demonstrates a practical application of these technologies within a large, integrated healthcare system.
The Significance of Independence for Verily
The shift in ownership structure, with Alphabet relinquishing its controlling stake, is a critical development for Verily. As explained by HIT Consultant, vendor neutrality is paramount in enterprise healthcare. Healthcare organizations are often wary of becoming overly reliant on technology companies affiliated with larger corporations, particularly those that may compete with their own internal initiatives. By establishing true corporate independence, Verily can position itself as a trusted partner for a wider range of healthcare providers and technology vendors.
This independence allows Verily to freely collaborate across the entire tech and medical ecosystem, fostering innovation and accelerating the adoption of precision health solutions. The company’s recent partnerships with Samsung and Salesforce are prime examples of this new collaborative approach, demonstrating its ability to integrate with leading technology platforms without concerns about conflicts of interest.
Key Takeaways
- $300 Million Investment: Verily has secured $300 million in funding led by Series X Capital to advance its precision health AI strategy.
- Independence from Alphabet: Alphabet will transition to a significant minority investor, granting Verily greater autonomy.
- AI-Native Platform: The funding will accelerate the development of an AI-native platform to harmonize healthcare data and deliver actionable insights.
- Strategic Partnerships: Verily is forging partnerships with Samsung and Salesforce to expand the reach of its platform.
- UCHealth and University of Colorado Anschutz Involvement: These institutions are actively using Verily’s Pre platform and have invested in the company.
The future of healthcare is increasingly reliant on data-driven insights and personalized treatment approaches. Verily’s commitment to precision health, coupled with its newfound independence and strategic partnerships, positions the company as a key player in this evolving landscape. The company’s next steps will likely involve expanding its platform’s capabilities, forging new collaborations, and demonstrating the tangible benefits of its AI-powered solutions in real-world clinical settings.
Verily Health Inc. Is expected to provide further updates on its progress and roadmap in the coming months. Readers interested in learning more about Verily’s perform can visit the company’s website at verily.com. The company’s continued development will be closely watched by industry experts and healthcare professionals alike, as it seeks to transform the future of healthcare through the power of AI and precision medicine.
What are your thoughts on Verily’s new direction? Share your comments below and let us know how you see AI impacting the future of healthcare.
Keep reading